Clinical Trial Update: Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating durvalumab with or without bavituximab in previously treated metastatic non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bavituximab (bavituximab)
• Durvalumab (durvalumab)

Snippet

Sponsor: Peregrine Pharmaceuticals | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN